Syncona
 | |
| Type | Public |
|---|---|
| LSE: SYNC FTSE 250 component | |
| Founded | 2012 |
| Headquarters | , |
Key people | Melanie Gee (chair) |
| Website | www |
Syncona (LSE: SYNC) is a large British closed-ended investment trust dedicated to life science investments. Co-founded as Syncona Partners in 2012 by former CEO Martin Murphy and the Wellcome Trust,[1] before merging with the Battle Against Cancer Investment Trust ('BACIT') in December 2016 and listing publicly,[2] the company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.[3] Its Chair is Melanie Gee.[4]
References
[edit]- ↑ "Wellcome Trust charity cuts stake in Syncona". Quoted Data. 14 March 2019. Retrieved 3 October 2025.
- ↑ "U.K. investors team up to create $1.2B cancer-focused fund". Fierce Biotech. 7 November 2016. Retrieved 3 October 2025.
- ↑ "BACIT Changes Name To Syncona After Investment Shift". Morning Star. 19 December 2016. Retrieved 4 March 2017.
- ↑ "Tigue exiting Syncona as investment banker Gee joins board". Citywire. 6 June 2019. Retrieved 5 August 2021.